Toxicological considerations for intravitreal drugs

Area of Science:

• Ophthalmology
• Pharmacology
• Toxicology

Background:

• Intravitreal injections are a primary method for delivering drugs to the retina.
• The increasing number of available and developing drugs necessitates a focus on safety.

Purpose of the Study:

• To review the toxicology and safety of common and emerging intravitreal drugs.
• To assess the efficacy and safety of key agents like bevacizumab, ranibizumab, and triamcinolone.

Main Methods:

• Review of toxicological considerations for anti-VEGFs, corticosteroids, and antibiotics.
• Discussion of emerging agents including anti-TNFs, VEGF-trap, and kinase inhibitors.
• Evaluation of efficacy and safety data for bevacizumab, ranibizumab, and triamcinolone.

Main Results:

• Established safety and toxicology profiles exist for several intravitreal drugs.
• Bevacizumab and ranibizumab are effective for wet-age-related macular degeneration and macular edema.
• Triamcinolone serves as an alternative for secondary macular edema.

Conclusions:

• Retinal pharmacotherapy is effective but carries risks of toxicity.
• Long-term toxicological effects of intravitreal drugs require further investigation.
• Ongoing research into drug safety is vital for optimizing intravitreal treatments.